Skip to main content
Roy Perlis, MD, Psychiatry, Boston, MA, Massachusetts General Hospital

RoyHowardPerlisMD

Psychiatry • Boston, MA

Director of the Center for Experimental Drugs and Diagnostics (CEDD) and Associate Director of the Psychiatric Genetics Program in Mood and Anxiety Disorders in the MGH Psychiatry Department Associate Professor of Psychiatry at Harvard Medical School and serves as a consultant to the American Psychiatric Association's bipolar treatment guidelines workshop

Join to view full profile

Dr. Perlis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Perlis' full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2001
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1997 - 1998
  • Harvard Medical School
    Harvard Medical SchoolClass of 1997

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1998 - 2026
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Psychiatry and COVID-19  
    Roy Perlis, Donald Goff, JAMA
  • Can Electronic Health Records Revive Central Nervous System Clinical Trials?  
    Maurizio Fava, Roy H Perlis, Nature
  • Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017  
    Roy Perlis, MD, JAMA

Lectures

  • Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-Wide Association Studies 
    162nd Annual Meeting, San Francisco, California, USA
  • Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging 
    American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA

Authored Content

  • The Time Has Come for Over-the-Counter AntidepressantsApril 2024
  • Genome-Wide Association Study of Dimensional Psychopathology Using Electronic Health RecordsFebruary 2018
  • High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health RecordsFebruary 2018

Press Mentions

  • 1 in 8 Patients with Long COVID Also Deal with Unemployment
    1 in 8 Patients with Long COVID Also Deal with UnemploymentMay 2nd, 2023
  • Mother's COVID-19 Could Impact Male Newborn's Cognitive Development
    Mother's COVID-19 Could Impact Male Newborn's Cognitive DevelopmentApril 28th, 2023
  • Study Finds COVID During Pregnancy Can Impact Brain Development in Male Infants
    Study Finds COVID During Pregnancy Can Impact Brain Development in Male InfantsApril 18th, 2023
  • Join now to see all

Grant Support

  • In Vitro And In Vivo Study Of Simvastatin PLUS Lithium In Bipolar DepressionNational Institute Of Mental Health2012
  • Building A Risk Stratification Model For Treatment Resistance In Major DepressiveNational Institute Of Mental Health2009–2011
  • Pramipexole In Treatment-Resistant DepressionNational Institute Of Mental Health2003–2007

Hospital Affiliations

Dr. Roy Perlis, Dr. Roy Perlis, MD, Dr. R Perlis, Dr. Roy Howard Perlis